Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
You may also be interested in...
The US president made what seemed to be a retaliatory statement about high drug prices after Merck CEO Ken Frazier resigned from his jobs council.
HRSA Administrator George Sigounas made his public debut during the annual 340B coalition summer conference in Washington, DC. The setting was significant giving the prominence of the drug discount program on the Trump Administration agenda, but Sigounas didn’t offer much insight into the potential changes to come.
Draft version of order signals a focus on insurance benefit design, accelerating drug approvals and de-regulation.